Evaluation of the clinical activity of ipilimumab (IPI) plus nivolumab (NIVO) in patients (pts) with NIVO-refractory metastatic urothelial cancer (UC) - Callahan, M K (J Clin Oncol, 2017)
(suppl 6S; abstract 384) DOI: 10.1200/JCO.2017.35.6_suppl.384, no. 6_suppl [February 2017])